Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous belimumab plus standard therapy in pediatric SLE (PK, safety, PD)
jRCT2080224941Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by GSK. Primary endpoints: Belimumab pharmacokinetics at Week 12 (serum concentration), Belimumab pharmacokinetic parameters (Cavg, Cmax, Cmin) and 1 more. Started Nov 2019; status: completed.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080224941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224941.